



A1

1636

1636

RECEIVED

AUG 07 2003

TECH CENTER 1636/290

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of :  
Ernest Arenas, et al. : Examiner: G. Leffers Jr.  
Serial No. 09/980,913 : Group Art Unit: 1636  
Filed: May 21, 2002 :  
Attorney Ref No: :  
0380-P02709US0 :  
For: MATERIALS AND METHODS :  
RELATING TO NEURONAL :  
DEVELOPMENT :

Certificate of Mailing Under 37 C.F.R. §1.8(a):

I hereby certify that this correspondence is being deposited on July 31, 2003 with the United States Postal Service as first-class mail in an envelope properly addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Lynn C. Fischer

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, applicants hereby submit the attached PTO Form-1449, listing references which the patent examiner is requested to consider and make of record in the above-identified application. Copies of the listed references are enclosed herewith. This submission is believed to be in full compliance with the requirements of 37 C.F.R. §1.98.

This information disclosure statement is being filed after receipt of the first Official Action but before the issuance of a final action or a notice of allowance. Accordingly, a fee of \$180.00 dollars is enclosed pursuant to 37 C.F.R. §1.97 (c) (2).

In the opinion of the undersigned, the foregoing references are the most pertinent of which the undersigned is aware. However, no representation is made or intended that more pertinent references do not exist.

This submission is not an admission that the references listed on the attached Form PTO-1449 constitute prior art against the claims of the application.

The Examiner is respectfully requested to confirm receipt and consideration of the cited references by initialing and returning a copy of the attached Form PTO-1449 in accordance with MPEP §609.

If there is any inaccuracy in this fee computation, please charge any additional fee or credit any overpayment to the Patent and Trademark Office Deposit Account, No. 04-1406.

Early and favorable consideration leading to prompt issuance of this application is earnestly solicited.

Respectfully submitted,

DANN, DORFMAN, HERRELL AND SKILLMAN  
A Professional Corporation

By Patrick J. Hagan  
Patrick J. Hagan  
Registration No. 27,643

Telephone: (215) 563-4100  
Facsimile: (215) 563-4044

<b>INFORMATION DISCLOSURE STATEMENT</b>	<i>Complete if known</i>	
	Application Number: 09/980,913	
	Filing Date: May 21, 2002	
	First Named Inventor: Ernest Arenas	
	Group Art Unit: 1636	
	Examiner Name: Gerald G. Leffers Jr.	
SHEET 1 OF 2		Our File No. 0380 PO 2709 US0

UNITED STATES PATENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1			

FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
	B1	WO 9615224 A	WO	05-23-1996	Weiss, Samuel et al.
	B2	WO 96 09543 A	WO	05-28-1996	Weiss, Samuel et al.

OTHER PRIOR ART - NON-PATENT DOCUMENTS		
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	E. Arenas et al., <u>Nurr1 overexpression enriches for neuronal phenotype in multipotent, neural stem-like cells</u> . SOCIETY FOR NEUROSCIENCE ABSTRACTS, 28 <sup>TH</sup> ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 2, LOS ANGELES, US , NOVEMBER 7-12, 1998, vol. 24, 1998, page 1531, Abstract 606.10.
	C2	D.M. Panchision et al., <u>An immortalized type-1 astrocyte of mesencephalic origin; source of a dopaminergic neurotrophic factor</u> . JOURNAL OF MOLECULAR NEUROSCIENCE, vol. 11, no. 3, 1998, pages 209-221.
	C3	T. Takeshima et al., <u>Astrocyte-dependent and -independent phases of the development and survival of rat embryonic day 14 mesencephalic, dopaminergic neurons in culture</u> . NEUROSCIENCE, vol. 60, no. 3, 1994, pages 809-823.
	C4	A. Gritti et al., <u>Basic fibroblast growth factor supports the proliferation of epidermal growth factor-generated neuronal precursors cells of the adult mouse CNS</u> . NEUROSCIENCE LETTERS, vol. 185, no. 3, 1995, pages 151-154.
	C5	O. Saucedo-Cardenas et al., <u>Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons</u> . PNAS USA, vol. 95, March 1998, pages 4013-4018.

EXAMINER'S SIGNATURE		DATE CONSIDERED	
----------------------	--	-----------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.

**INFORMATION  
DISCLOSURE  
STATEMENT**

*Complete if known*

Application Number: 09/980,913

Filing Date: May 21, 2002

First Named Inventor: Ernest Arenas

Group Art Unit: 1636

Examiner Name: Gerald G. Leffers Jr.

SHEET 2 OF 2

Our File No. 0380 PO 2709 US0

C6	J. Wagner et al., <u>Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes</u> . NATURE BIOTECHNOLOGY, vol. 17, July 1999, pages 653-659.
C7	K. Sakurada et al., <u>Nurr1, an orphan nuclear receptor is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain</u> . DEVELOPMENT, vol. 126, September 1999, pages 4017-4026.
C8	S. Denis-Donini et al., <u>Glial heterogeneity may define the three-dimensional shape of mouse mesencephalic dopaminergic neurones</u> . NATURE, vol. 307, February 1984, pages 641-643.

EXAMINER'S  
SIGNATURE

DATE  
CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.